Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Arrowhead Pharmaceuticals
Age
18–65
Sex
ALL
Healthy volunteers
Accepted
You may be eligible if
Normal pulmonary function tests at Screening (NHVs only)
Confirmed diagnosis of asthma based on source verifiable medical record (asthma patients only)
No abnormal finding of clinical relevance at Screening (other than asthma for asthma patients)
Stable dose of asthma controller medications prior to Screening (asthma patients only)
If on allergen-specific immunotherapy, participants must be on a stable maintenance dose
Non-smoking
Women of childbearing potential must have a negative pregnancy test, cannot be breastfeeding, and must be willing to use contraception. Males must not donate sperm during the study and for at least 12 weeks following the last dose of study drug
Willing to provide written informed consent and to comply with study requirements
You may not be if
Acute lower respiratory infection or asthma exacerbation within 30 days prior to first dose
Positive COVID-19 test during Screening window
Use of immunosuppressive medication within 90 days prior to first dose
Receipt of any intranasal vaccine within 30 days prior to first dose
Use of systemic corticosteroid therapy within 90 days prior to first dose
Clinically significant health concerns (other than asthma in asthma patients)
Human Immunodeficiency virus (HIV) infection, seropositive for Hepatitis B Virus (HBV), seropositive for Hepatitis C Virus (HCV)
Uncontrolled hypertension
Unwilling to limit alcohol consumption to within moderate limits for the duration of the study
Use of illicit drugs
Use of an investigational agent or device within 30 days prior to first dose
